Mark Cuban’s Online Pharmacy Shakes Up Drug Prices—See How Much You Could Save

America’s drug-price disruptor is accelerating Affordable prescriptions for hospitals In early March, Mark Cuban Cost Plus Drug Company (MCCPDC) inked a strategic distribution pact that lets its no-middleman medicines flow directly to U.S. hospitals, widening access to more than 2,300 generics at transparent prices. Health-system buyers can now bypass the traditional group-purchasing maze and order online, paying only the drug’s acquisition cost plus a 15 % margin and a fixed pharmacy fee. Targeting pharmacy deserts MCCPDC is also piloting brick-and-mortar collaborations in underserved zip codes after a wave of chain closures left millions without a neighborhood pharmacy. The company says it is reviewing micro-fulfillment kiosks, independent-store buy-ins and mail-order lockers to “erase the last mile” for rural and inner-city patients hurt by pharmacy deserts. Biosimilars and specialty drugs join the catalog To prove its model scales beyond inexpensive generics, MCCPDC just added Starjemza (ustekinumab-hmny), a biosimilar for inflammatory bowel disease and psoriasis, at an introductory price of $375 per 45 mg vial—roughly 85 % below prevailing list prices. More complex biologics are slated for release throughout 2026 as manufacturing partners come online. Insurers take notice Humana is in exploratory talks with MCCPDC to funnel members’ e-prescriptions through the Cost Plus platform, a move that could slash plan spend without locking consumers into restrictive formularies. Industry analysts predict that even a limited partnership would pressure pharmacy-benefit managers (PBMs) to reveal spread pricing or risk member defections. Mark Cuban’s bigger vision Speaking at HealthCare Brew Live, Cuban argued that transparency, not legislation, is the fastest route to lower national drug spend. “If we force prices into the sunlight, PBMs will compete on service instead of rebates,” he said, hinting at upcoming real-time price tools for prescribers and patients. Why this matters for searchers • Cash-pay prices often beat insured co-pays. • Hospital pharmacies can join the platform today. • New delivery pilots may reopen shuttered pharmacy deserts. • Specialty-drug discounts are expanding beyond antibiotics and statins. • Major insurers are eyeing Cost Plus integrations. Bottom line Mark Cuban’s pharmacy startup is morphing from an e-commerce curiosity into a supply-chain alternative that hospitals, insurers and patients can’t ignore. As MCCPDC adds biosimilars, conquers pharmacy deserts and courts insurers, the pressure on legacy PBMs to justify opaque markups is about to reach a tipping point.